

SPECIAL FEATURES

CCR Pediatric Oncology Series

Complimentary access to this online-only series of articles from the AACR Childhood Cancer Predisposition Workshop:
clincancerres.aacrjournals.org/pediatricseries

- e46** **Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1**
D. Gareth R. Evans, Hector Salvador, Vivian Y. Chang, Ayelet Erez, Stephan D. Voss, Kami Wolfe Schneider, Hamish S. Scott, Sharon E. Plon, and Uri Tabori
- e54** **Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders**
D. Gareth R. Evans, Hector Salvador, Vivian Y. Chang, Ayelet Erez, Stephan D. Voss, Harriet Druker, Hamish S. Scott, and Uri Tabori
- e62** **Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome**
William D. Foulkes, Junne Kamihara, D. Gareth R. Evans, Laurence Brugières, Franck Bourdeaut, Jan J. Molenaar, Michael F. Walsh, Garrett M. Brodeur, and Lisa Diller
- e68** **Von Hippel–Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood**
Surya P. Rednam, Ayelet Erez, Harriet Druker, Katherine A. Janeway, Junne Kamihara, Wendy K. Kohlmann, Katherine L. Nathanson, Lisa J. States, Gail E. Tomlinson, Anita Villani, Stephan D. Voss, Joshua D. Schiffman, and Jonathan D. Wasserman
- e76** ***PTEN*, *DICER1*, *FH*, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood**
Kris Ann P. Schultz, Surya P. Rednam, Junne Kamihara, Leslie Doros, Maria Isabel Achatz, Jonathan D. Wasserman, Lisa R. Diller, Laurence Brugières, Harriet Druker, Katherine A. Schneider, Rose B. McGee, and William D. Foulkes
- e83** **Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk**
Anita Villani, Mary-Louise C. Greer, Jennifer M. Kalish, Akira Nakagawara, Katherine L. Nathanson, Kristian W. Pajtler, Stefan M. Pfister, Michael F. Walsh, Jonathan D. Wasserman, Kristin Zelle, and Christian P. Kratz

Highlights of This Issue 2919

CCR Translations

- 2921** **The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1**
James S. Wilmott, Helen Rizos, Richard A. Scolyer, and Georgina V. Long
See related article, p. 3168

CCR Drug Updates

- 2924** **FDA Approval Summary: TAS-102**
Leigh Marcus, Steven J. Lemery, Sachia Khasar, Emily Wearne, Whitney S. Helms, Weishi Yuan, Kun He, Xianhua Cao, Jingyu Yu, Hong Zhao, Yaning Wang, Olen Stephens, Erika Englund, Rajiv Agarwal, Patricia Keegan, and Richard Pazdur

Molecular Pathways

- 2928** **Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion—A New Role for the AXL Receptor Tyrosine Kinase**
Todd A. Aguilera and Amato J. Giaccia
- 2934** **Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target**
Heather L. MacGregor and Pamela S. Ohashi

CANCER THERAPY: CLINICAL

- 2942** **Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody**
George A. Dominguez, Thomas Condamine, Sridevi Mony, Ayumi Hashimoto, Fang Wang, Qin Liu, Andres Forero, Johanna Bendell, Robert Witt, Neil Hockstein, Prasanna Kumar, and Dmitry I. Gabrilovich
- 2951** **Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients**
Jana Portnow, Timothy W. Synold, Behnam Badie, Revathiswari Tirughana, Simon F. Lacey, Massimo D'Apuzzo, Marianne Z. Metz, Joseph Najbauer, Victoria Bedell, Tien Vo, Margarita Gutova, Paul Frankel, Mike Chen, and Karen S. Aboody



Table of Contents

- 2961** Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2^{POS} DCIS Independent of Route: Results of Randomized Selection Design Trial



Lea Lowenfeld, Rosemarie Mick, Jashodeep Datta, Shuwen Xu, Elizabeth Fitzpatrick, Carla S. Fisher, Kevin R. Fox, Angela DeMichele, Paul J. Zhang, Susan P. Weinstein, Robert E. Roses, and Brian J. Czerniecki

- 2972** Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab

Sandra P. D'Angelo, Alexander N. Shoushtari, Mary Louise Keohan, Mark A. Dickson, Mrinal M. Gounder, Ping Chi, Jennifer K. Loo, Leigh Gaffney, Lee Schneider, Zarine Patel, Joseph Patrick Erinjeri, Mark J. Bluth, Ana Sjoberg, Howard Streicher, Naoko Takebe, Li-Xuan Qin, Cristina Antonescu, Ronald P. DeMatteo, Richard D. Carvajal, and William D. Tap

- 2981** Antitumor Activity of RXDX-105 in Multiple Cancer Types with *RET* Rearrangements or Mutations



Gang G. Li, Romel Somwar, James Joseph, Roger S. Smith, Takuo Hayashi, Leenus Martin, Aleksandra Franovic, Anni Schairer, Eric Martin, Gregory J. Riely, Jason Harris, Shunqi Yan, Ge Wei, Jennifer W. Oliver, Rupal Patel, Pratik Multani, Marc Ladanyi, and Alexander Drilon

- 2991** Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer

Kelly K. Hunt, Cansu Karakas, Min Jin Ha, Anna Biernacka, Min Yi, Aysegul A. Sahin, Opoku Adjapong, Gabriel N. Hortobagyi, Melissa L. Bondy, Patricia A. Thompson, Kwok Leung Cheung, Ian O. Ellis, Sarah Bacus, W. Fraser Symmans, Kim-Anh Do, and Khandan Keyomarsi

- 3003** A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with *FGFR3* Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157

Noah M. Hahn, Trinity J. Bivalacqua, Ashley E. Ross, George J. Netto, Alex Baras, Jong Chul Park, Carolyn Chapman, Timothy A. Masterson, Michael O. Koch, Richard Bihrl, Richard S. Foster, Thomas A. Gardner, Liang Cheng, David R. Jones, Kyle McElyea, George E. Sandusky, Timothy Breen, Ziyue Liu, Costantine Albany, Marietta L. Moore, Rhoda L. Loman, Angela Reed, Scott A. Turner, Francine B. De Abreu, Torrey Gallagher, Gregory J. Tsongalis, Elizabeth R. Plimack, Richard E. Greenberg, and Daniel M. Geynisman

- 3012** Potential Predictive Value of *TP53* and *KRAS* Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, Jian Su, Zhi Xie, Si-Yang Liu, Hai-Yan Tu, Hua-Jun Chen, Yue-Li Sun, Qing Zhou, Jin-Ji Yang, Xue-Ning Yang, Jia-Xin Lin, Hong-Hong Yan, Hao-Ran Zhai, Li-Xu Yan, Ri-Qiang Liao, Si-Pei Wu, and Yi-Long Wu

PERSONALIZED MEDICINE AND IMAGING

- 3025** An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

Françoise Solly, Catherine Koering, Aminetou Mint Mohamed, Delphine Maucourt-Boulch, Guillaume Robert, Patrick Auberger, Pascale Flandrin-Gresta, Lionel Adès, Pierre Fenaux, Olivier Kosmider, Emmanuelle Tavernier-Tardy, Jérôme Cornillon, Denis Guyotat, Lydia Campos, Franck Mortreux, and Eric Wattel

- 3035** A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse



Alex Prat, Ana Lluch, Arran K. Turnbull, Anita K. Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, José Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montserrat Muñoz, Laia Paré, Joel S. Parker, Nuria Ribelles, Begoña Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva Carrasco, Miguel Martín, J. Michael Dixon, Charles M. Perou, and Emilio Alba

- 3045** Noninvasive Measurement of mTORC1 Signaling with ⁸⁹Zr-Transferrin

Charles Truillet, John T. Cunningham, Matthew F.L. Parker, Loc T. Huynh, Crystal S. Conn, Davide Ruggero, Jason S. Lewis, and Michael J. Evans

- 3053** ¹⁸F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials

Yingbing Wang, Karen L. Ayres, Debra A. Goldman, Maura N. Dickler, Aditya Bardia, Ingrid A. Mayer, Eric Winer, Jill Fredrickson, Carlos L. Arteaga, José Baselga, Henry C. Manning, Umar Mahmood, and Gary A. Ulaner

Table of Contents

CANCER THERAPY: PRECLINICAL

3061 Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues

Ashwini Balakrishnan, Tracy Goodpaster, Julie Randolph-Habecker, Benjamin G. Hoffstrom, Florencia G. Jalikis, Lisa K. Koch, Carolina Berger, Paula L. Kosasih, Anusha Rajan, Daniel Sommermeyer, Peggy L. Porter, and Stanley R. Riddell

3072 Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV⁺ Patients



Toni M. Brand, Stefan Hartmann, Neil E. Bhola, Noah D. Peyser, Hua Li, Yan Zeng, Erin Isaacson Wechsler, Max V. Ranall, Sourav Bandyopadhyay, Umamaheswar Duvvuri, Theresa M. LaVallee, Richard C.K. Jordan, Daniel E. Johnson, and Jennifer R. Grandis

3084 Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib

Jennifer E. Amengual, Sathyen A. Prabhu, Maximilian Lombardo, Kelly Zullo, Paul M. Johannet, Yulissa Gonzalez, Luigi Scotto, Xavier Jirau Serrano, Ying Wei, Jimmy Duong, Renu Nandakumar, Serge Cremers, Akanksha Verma, Olivier Elemento, and Owen A. O'Connor

3097 Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models

Hyoung Kim, Erin George, Ryan L. Ragland, Stavros Rafail, Rugang Zhang, Clemens Krepler, Mark A. Morgan, Meenhard Herlyn, Eric J. Brown, and Fiona Simpkins

3109 Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells



Prajwal Rajappa, William S. Cobb, Emma Vartanian, Yujie Huang, Laura Daly, Caitlin Hoffman, Jane Zhang, Beiyi Shen, Rachel Yanowitch, Kunal Garg, Babacar Cisse, Sara Haddock, Jason Huse, David J. Pisapia, Timothy A. Chan, David C. Lyden, Jacqueline F. Bromberg, and Jeffrey P. Greenfield

3129 Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer

David Balli, Andrew J. Rech, Ben Z. Stanger, and Robert H. Vonderheide

3139 Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer

Azusa Tanimoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Tadaaki Yamada, Xavier Roca, S. Tiong Ong, and Seiji Yano

3150 Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and *In Situ* Hybridization

Matthias Holdhoff, Gunes Guner, Fausto J. Rodriguez, Jessica L. Hicks, Qizhi Zheng, Michael S. Forman, Xiaobu Ye, Stuart A. Grossman, Alan K. Meeker, Christopher M. Heaphy, Charles G. Eberhart, Angelo M. De Marzo, and Ravit Arav-Boger

3158 PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Jennifer H. Yearley, Christopher Gibson, Ni Yu, Christina Moon, Erin Murphy, Jonathan Juco, Jared Lunceford, Jonathan Cheng, Laura Q.M. Chow, Tangyu Y. Seiwert, Masahisa Handa, Joanne E. Tomassini, and Terrill McClanahan

3168 Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy



Maria L. Ascierto, Alvin Makohon-Moore, Evan J. Lipson, Janis M. Taube, Tracee L. McMiller, Alan E. Berger, Jinshui Fan, Genevieve J. Kaunitz, Tricia R. Cottrell, Zachary A. Kohutek, Alexander Favorov, Vladimir Makarov, Nadeem Riaz, Timothy A. Chan, Leslie Cope, Ralph H. Hruban, Drew M. Pardoll, Barry S. Taylor, David B. Solit, Christine A. Iacobuzio-Donahue, and Suzanne L. Topalian
See related commentary, p. 2921

3181 Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho

Reeti Behera, Amanpreet Kaur, Marie R. Webster, Suyeon Kim, Abibatou Ndoye, Curtis H. Kugel III, Gretchen M. Alicea, Joshua Wang, Kanad Ghosh, Phil Cheng, Sofia Lisanti, Katie Marchbank, Vanessa Dang, Mitchell Levesque, Reinhard Dummer, Xiaowei Xu, Meenhard Herlyn, Andrew E. Aplin, Alexander Roesch, Cecilia Caino, Dario C. Altieri, and Ashani T. Weeraratna

BIOLOGY OF HUMAN TUMORS

3120 Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squamous Cell Carcinoma

Naoshad Muhammad, Sourav Bhattacharya, Robert Steele, Nancy Phillips, and Ratna B. Ray



Table of Contents

3191 Co-occurring Mutations of Tumor Suppressor Genes, *LATS2* and *NF2*, in Malignant Pleural Mesothelioma

Robin Tranchant, Lisa Quetel, Anne Tallet, Clement Meiller, Annie Renier, Leanne de Koning, Aurelien de Reynies, Françoise Le Pimpec-Barthes, Jessica Zucman-Rossi, Marie-Claude Jaurand, and Didier Jean

3203 Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies *B2M* Inactivation Impairing Immunorecognition

Carolina Pereira, Pol Gimenez-Xavier, Eva Pros, María J. Pajares, Massimo Moro, Antonio Gomez, Alejandro Navarro, Enric Condom, Sebastian Moran, Gonzalo Gomez-Lopez, Osvaldo Graña, Miriam Rubio-Camarillo, Alex Martinez-Martí, Jun Yokota, Julian Carretero, Jose M. Galbis, Ernest Nadal, David Pisano, Gabriella Sozzi, Enriqueta Felip, Luis M. Montuenga, Luca Roz, Alberto Villanueva, and Montse Sanchez-Céspedes

3214 Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma

Kent W. Mouw, James M. Cleary, Brendan Reardon, Jonathan Pike, Lior Z. Braunstein, Jaegil Kim, Ali Amin-Mansour, Diana Miao, Alexis Damish, Joanna Chin, Patrick A. Ott, Charles S. Fuchs, Neil E. Martin, Gad Getz, Scott Carter, Harvey J. Mamon, Jason L. Hornick, Eliezer M. Van Allen, and Alan D. D'Andrea

LETTERS TO THE EDITOR

3223 Inhibitor of Pancreatic Cancer by *RHIL1RA*—Letter



Sinan Lu, Shusen Zheng, and Weilin Wang

3224 Inhibition of Pancreatic Cancer by *RhIL1RA*—Response

Paul J. Chiao, Jianhua Ling, Jie Fu, Yu Lu, and Yi-Chen Sun

CORRECTIONS

3225 Correction: Frequent Overexpression of *HMG2* in Human Atypical Teratoid/Rhabdoid Tumor and Its Correlation with *let-7a3/let-7b* miRNA

3226 Correction: Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances

 AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows a section of an oropharynx tumor from a patient with HPV-associated head and neck cancer. Immunohistochemical staining shows strong membranous HER3 expression in a small area of the tumor. For details, see the article by Brand and colleagues on page 3072 of this issue.

